CN117255800A - 具有抗体恒定区变体的结合分子的多聚化 - Google Patents

具有抗体恒定区变体的结合分子的多聚化 Download PDF

Info

Publication number
CN117255800A
CN117255800A CN202280030416.0A CN202280030416A CN117255800A CN 117255800 A CN117255800 A CN 117255800A CN 202280030416 A CN202280030416 A CN 202280030416A CN 117255800 A CN117255800 A CN 117255800A
Authority
CN
China
Prior art keywords
antigen
igg
molecule
human
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030416.0A
Other languages
English (en)
Chinese (zh)
Inventor
程儒进
范斌
西蒙·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Priority to CN202410422718.3A priority Critical patent/CN118359707A/zh
Publication of CN117255800A publication Critical patent/CN117255800A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202280030416.0A 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化 Pending CN117255800A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410422718.3A CN118359707A (zh) 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163180969P 2021-04-28 2021-04-28
US63/180,969 2021-04-28
PCT/US2022/026505 WO2022232246A1 (en) 2021-04-28 2022-04-27 Multimerization of binding molecules having an antibody constant region variant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410422718.3A Division CN118359707A (zh) 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化

Publications (1)

Publication Number Publication Date
CN117255800A true CN117255800A (zh) 2023-12-19

Family

ID=83847261

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202280030416.0A Pending CN117255800A (zh) 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化
CN202410422718.3A Pending CN118359707A (zh) 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410422718.3A Pending CN118359707A (zh) 2021-04-28 2022-04-27 具有抗体恒定区变体的结合分子的多聚化

Country Status (7)

Country Link
US (1) US20240209116A1 (https=)
EP (1) EP4330277A4 (https=)
JP (1) JP2024516392A (https=)
CN (2) CN117255800A (https=)
AU (1) AU2022266780A1 (https=)
CA (1) CA3216755A1 (https=)
WO (1) WO2022232246A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6509724B2 (ja) * 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법

Also Published As

Publication number Publication date
CN118359707A (zh) 2024-07-19
WO2022232246A1 (en) 2022-11-03
US20240209116A1 (en) 2024-06-27
AU2022266780A9 (en) 2023-11-16
EP4330277A1 (en) 2024-03-06
JP2024516392A (ja) 2024-04-15
EP4330277A4 (en) 2025-03-26
AU2022266780A1 (en) 2023-11-09
CA3216755A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
CN110678482A (zh) 包含pd-1结合蛋白的制剂及其制备方法
US20240182582A1 (en) Materials and methods for immune effector cells redirection
JP2023542337A (ja) Ｅｇｆｒ結合複合体、その製造及び使用方法
CN118647629A (zh) 含有TNF-α的免疫缀合物及其相关方法和组合物
US20250230254A1 (en) Biosynthetic bioparatopic or bispecific binding molecules with enhanced effector functions
US20240209116A1 (en) Multimerization of binding molecules having an antibody constant region variant
JP2024540931A (ja) 増強されたエフェクター機能を有する生物合成一価結合分子
CN119529092A (zh) 抗acvr2a抗体及其用途
CN116917329A (zh) Gucy2c结合分子及其用途
US20220267456A1 (en) Materials and methods for targeting regulatory t cells for enhancing immune surveillance
WO2023240067A2 (en) Multimerization of binding molecules having an antibody constant region variant and mutations that reduce effector functions
TW202337904A (zh) ＩＬ－１β結合蛋白之材料及方法
US20240218083A1 (en) Molecules with engineered antibody constant region variants
CN117545505A (zh) 具有工程化抗体恒定区变体的分子
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
CN121002064A (zh) 抗lilrb1和/或抗lilrb2抗体及其用途
HK40118046A (zh) 抗acvr2a抗体及其用途
HK40107782A (zh) 抗acvr2a抗体及其用途
CN121909215A (zh) 抗acvr2b抗体及其用途
CN119948051A (zh) 用于改善抗原结合可变区的生物工程化配对的材料和方法
CN117500836A (zh) 用于免疫效应细胞重定向的材料和方法
HK40119194A (zh) IL-1β结合蛋白的材料和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination